Back to Directory
Abarelix
Performance & EnduranceGnRH antagonist for prostate cancer, withdrawn due to allergic reactions.
Key Benefits
- ✓Was used for prostate cancer
- ✓Withdrawn from market
- ✓Replaced by degarelix
Dosing Information
Dosage Range
Not available
Frequency
Withdrawn
Typical Duration
N/A
Detailed Protocol
Withdrawn from market in 2005. No longer available.
About Abarelix
Abarelix (Plenaxis) was a GnRH antagonist peptide FDA-approved for prostate cancer. Withdrawn from market due to high rate of serious immediate-onset systemic allergic reactions. Replaced by degarelix.
Research Notes
FDA-approved 2003, voluntarily withdrawn 2005 due to 1.5% rate of serious allergic reactions. Historical example of why newer agents (degarelix) preferred.
Potential Side Effects
- •High allergy rate led to withdrawal
- •No longer available
Always consult with a healthcare professional before starting any peptide therapy.